Expanded Access for Abatacept

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

NCT06581562 ·Status: RECRUITING ·Phase: PHASE1

Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy

NCT01765842 ·Status: TERMINATED ·Phase: PHASE3

Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg

NCT00705367 ·Status: COMPLETED ·Phase: PHASE1

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871 ·Status: COMPLETED ·Phase: PHASE2

Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis

NCT00293072 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

NCT06713590 ·Status: COMPLETED ·Phase: PHASE1

ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)

NCT05347992 ·Status: COMPLETED

Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2

Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis

NCT03526042 ·Status: UNKNOWN ·Phase: NA

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

NCT02725515 ·Status: COMPLETED ·Phase: PHASE2

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

NCT02070978 ·Status: TERMINATED ·Phase: PHASE2

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT04895696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Rituximab Vasculitis Maintenance Study

NCT01697267 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

NCT03252587 ·Status: COMPLETED ·Phase: PHASE2

Acquired Immunodeficiency in ANCA Associated Vasculitis

NCT03514979 ·Status: UNKNOWN ·Phase: PHASE2

Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

NCT01408576 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

NCT03943147 ·Status: TERMINATED ·Phase: PHASE2

Anifrolumab Early Access Program

NCT04750057 ·Status: NO_LONGER_AVAILABLE

Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus

NCT02533570 ·Status: TERMINATED ·Phase: PHASE2

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

NCT03616912 ·Status: TERMINATED ·Phase: PHASE3

Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)

NCT00997100 ·Status: COMPLETED ·Phase: PHASE2

Anti-CD20 in Systemic Lupus Erythematosus

NCT00036491 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852 ·Status: COMPLETED ·Phase: PHASE2

An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

NCT05798117 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2